Methods for treating multiple myeloma with anti-cd38 antibody combined with bortezomib, lenalidomide and dexamethasone.

CL202600831A1Pending Publication Date: 2026-08-14JANSSEN BIOTECH INC

View PDF 0 Cites 0 Cited by

Patent Information

Application Number: CL202600831
Authority / Receiving Office: CL · CL
Patent Type: Applications
Current Assignee / Owner
Priority Date: 2024-10-11
Filing Date: 2026-03-20
Publication Date: 2026-08-14

Application Information

Patent Timeline

11 Oct 2024

Priority

20 Mar 2026

Application

CL202600831

14 Aug 2026

Publication

CL202600831A1

IPC: A61K31/454; A61K31/573; A61K38/00; A61K38/05; A61K38/47; A61K39/395; A61K45/06; A61K47/18; A61K47/26; A61P35/00; C07K16/28

CPC: C07K16/2896; A61P35/00; A61K2039/505; A61K2039/545; A61K39/395; A61K47/26; A61K47/18; A61K31/573

Inventors: CARSON Robin; CHIU Christopher

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

Patent Text Reader

Abstract

This disclosure relates to methods for the treatment of multiple myeloma. This disclosure relates to methods for the treatment of newly diagnosed multiple myeloma in a patient in need, for example, by subcutaneous administration to the patient of a pharmaceutical composition comprising an anti-CD38 antibody in combination with bortezomib, lenalidomide, and dexamethasone.

Need to check novelty before this filing date? Find Prior Art